RapidEye
Regeneron Pharmaceuticals (NASDAQ:REGN), the maker of eye disease therapy Eylea, has acquired Oxular, a U.K.-based biotech drug developer focused on ophthalmology.
While neither company formally disclosed the deal, former Oxular CEO Mark Gaffney, who currently leads immunology drug developer Calluna Pharma, shared a